Welcome to our dedicated page for Altimmune news (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune stock.
Altimmune, Inc. (Nasdaq: ALT) generates a steady flow of news as a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver, metabolic and cardiometabolic diseases. Most company updates center on its lead investigational medicine, pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), alcohol-associated liver disease (ALD) and obesity.
News coverage of ALT frequently highlights clinical trial milestones. Altimmune issues detailed press releases on the IMPACT Phase 2b trial in MASH, including 24-week and 48-week topline data, changes in non-invasive tests of fibrosis and hepatic inflammation, and AI-based digital pathology analyses of liver biopsies. Additional updates describe progress in the RECLAIM Phase 2 trial in AUD and the RESTORE Phase 2 trial in ALD, including enrollment status and expected timelines for topline results.
Investors and followers of ALT stock also see regulatory and scientific news, such as Fast Track designations for pemvidutide in MASH and AUD, Breakthrough Therapy Designation for MASH, and publication of IMPACT trial data in peer-reviewed journals. Presentations at major medical meetings, including late-breaking oral and poster sessions at The Liver Meeting hosted by the American Association for the Study of Liver Diseases (AASLD), are common subjects of company announcements.
Altimmune’s news flow further includes corporate and financial updates. These range from quarterly financial results and business updates to CEO succession plans, executive appointments, term loan amendments and at-the-market equity offering arrangements disclosed in SEC filings and companion press releases. For anyone tracking ALT, this news page brings together clinical, regulatory, scientific and corporate developments in one place, making it easier to follow how Altimmune’s programs and capital strategy evolve over time.
Altimmune (Nasdaq: ALT) closed an oversubscribed underwritten public offering that generated approximately $225 million of gross proceeds at closing on April 27, 2026. The offering included 64,250,000 common shares and accompanying common stock warrants, plus up to 10,750,000 pre-funded warrants and accompanying warrants.
The combined offering price was $3.00 per share-and-warrant (pre-funded combos at $2.999). Proceeds are intended to fund the planned Phase 3 MASH trial and provide cash runway through the anticipated 52-week data readout; the company expects to initiate Phase 3 in H2 2026.
Altimmune (Nasdaq: ALT) priced an oversubscribed underwritten offering expected to raise approximately $225 million in gross proceeds. The deal comprises 64,250,000 common shares and accompanying warrants, plus up to 10,750,000 pre-funded warrants and accompanying warrants.
Combined offering prices are $3.00 per share-plus-warrant and $2.999 per pre-funded-warrant-plus-warrant; warrants exercise at $3.00, expire on the fifth anniversary or 45 days after a Phase 3 pemvidutide MASH successful readout. Proceeds are intended to fund the Phase 3 MASH trial, working capital and general corporate purposes.
Altimmune (Nasdaq: ALT) commenced a proposed underwritten public offering of common stock, pre-funded warrants and accompanying common stock warrants on April 22, 2026. The offering is subject to market conditions and may not be completed. Altimmune intends to use net proceeds to fund its upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH) and for working capital and general corporate purposes. Leerink Partners and Barclays are joint bookrunners; Titan Partners is co-bookrunner. Securities will be offered under previously effective Form S-3 shelf registration statements and a preliminary prospectus supplement will be filed with the SEC.
Altimmune (Nasdaq: ALT) reported Q4 and full‑year 2025 results and provided clinical and corporate updates on March 5, 2026. Key items: $274M cash and short‑term investments at Dec 31, 2025 (up ~107% YoY), a $75M registered direct offering in Jan 2026, FDA Breakthrough Therapy Designation for pemvidutide in MASH, and planned Phase 3 MASH initiation in 2026.
Topline RECLAIM Phase 2 AUD data expected Q3 2026; RESTORE ALD Phase 2 enrollment ongoing. 2025 R&D was $66.4M, G&A $28.1M, and net loss reported as $88.1M for the year.
Altimmune (Nasdaq: ALT) said management will attend four investor conferences March 9–12, 2026, offering one-on-one meetings and several fireside chats.
Webcasts of fireside chats at Leerink, Citizens and Barclays will be available via the company Events page; registered investors may request meetings through bank sales contacts.
Altimmune (Nasdaq: ALT) will report fourth quarter and full year 2025 financial results on March 5, 2026. Management will host a conference call and webcast at 8:30 a.m. ET to discuss results and provide a business update.
According to Altimmune, the live webcast will be available on the company's Investor Relations website, dial-in registration is required for participants, and a replay will be accessible for up to three months.
Altimmune (Nasdaq: ALT) closed a registered direct offering raising approximately $75 million gross through sale of 17,045,454 shares of common stock (or pre-funded warrants) on Jan 29, 2026. Proceeds will fund the planned Phase 3 pemvidutide trial for MASH, plus working capital and general corporate purposes. The pre-funded warrants are exercisable immediately at $0.001 per share. Titan Partners acted as sole placement agent; the offering was made from an effective shelf registration declared effective Dec 5, 2025.
Altimmune (Nasdaq: ALT) priced a registered direct offering expected to raise approximately $75 million of gross proceeds through the sale of 17,045,454 common shares (or pre-funded warrants), with closing expected on or about January 29, 2026.
Altimmune said it intends to use net proceeds to fund preparation for its planned Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH), plus working capital and general corporate purposes. The company cited Phase 2b 48-week topline data and a Breakthrough Therapy Designation from the U.S. FDA for pemvidutide.
Altimmune (NASDAQ: ALT) announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for pemvidutide to treat metabolic dysfunction-associated steatohepatitis (MASH) on January 5, 2026. The designation was based on 24-week IMPACT Phase 2b data showing statistically significant MASH resolution without worsening fibrosis and early improvements in liver fat and non-invasive fibrosis/inflammation tests.
Altimmune reported 48-week topline data in December 2025 showing further statistically significant improvements in ELF and LSM, continued weight loss at the 1.8 mg dose, and a favorable tolerability profile. The company and FDA aligned on registrational Phase 3 parameters and plan a 52-week, biopsy-endpoint Phase 3 using multiple doses and AIM-MASH AI Assist; European scientific advice will also be sought.
Altimmune (Nasdaq: ALT) reported positive 48-week topline results from the IMPACT Phase 2b trial of pemvidutide in MASH patients on Dec 19, 2025. Both 1.2 mg and 1.8 mg doses produced statistically significant improvements in noninvasive fibrosis markers versus placebo, including ELF (‑0.49 and ‑0.58 vs +0.16; p<0.0001) and LSM (‑3.04 and ‑3.97 vs ‑0.03; p<0.05/0.001).
Additional 48-week highlights: liver fat down 45.2% and 54.7% (vs 8.2% placebo), ALT reductions ~‑38 IU/L (vs ‑10.3), weight loss 4.5% and 7.5% (vs 0.2%), low discontinuations, and FDA End‑of‑Phase 2 alignment to advance to a registrational Phase 3 planned for 2026.